BioSpecifics Technologies Corp. Investor Presentation Now Available for On-demand Viewing at

   BioSpecifics Technologies Corp. Investor Presentation Now Available for
              On-demand Viewing at

Company invites individual and institutional investors to log-on to view

PR Newswire

NEW YORK, Dec. 10, 2012

NEW YORK, Dec. 10, 2012 /PRNewswire/ is
pleased to announce that BioSpecifics Technologies Corp.'s (NASDAQ: BSTC)
December 6th presentation is now available for
on-demand viewing. BioSpecifics is a biopharmaceutical company developing
first in class collagenase-based products marketed as XIAFLEX® in the U.S. and
XIAPEX® in Europe and Eurasia.

LINK: > red "register/ watch event now"

BioSpecifics Technologies Corp.'s presentation will be available 24/7 for 90
days. Investors may download shareholder materials from the "virtual trade
booth" for the next three weeks.

BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. (Nasdaq GM: BSTC) is a biopharmaceutical
company that has developed injectable collagenase for twelve clinical
indications. Injectable collagenase is currently marketed as XIAFLEX® in the
U.S. for the treatment of adult Dupuytren's contracture patients with a
palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is approved for
Dupuytren's contracture in the European Union and Canada. XIAFLEX is also in
clinical development for the treatment of several additional promising
indications: Auxilium recently submitted a supplemental Biologics License
Application (sBLA) to the FDA for XIAFLEX for the potential treatment of
Peyronie's disease based on positive results reported from its two Phase III
clinical studies. Auxilium is also testing XIAFLEX for frozen shoulder
syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib
clinical trials, respectively. BioSpecifics is currently managing the clinical
development of XIAFLEX for the treatment of human lipoma and canine lipoma,
which are both in Phase II clinical trials. Auxilium is currently partnered
with Asahi Kasei Pharma Corporation for the development and commercialization
of injectable collagenase for Dupuytren's contracture and Peyronie's disease
in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in
Canada, Australia, Brazil and Mexico. Pfizer Inc. has marketing rights to
XIAPEX® (the EU trade name for XIAFLEX) for Dupuytren's contracture in 46
countries in Eurasia through April 24, 2013. For more information, please


Since 2010, has been the only monthly virtual
investor conference series that provides an interactive forum for presenting
companies to meet directly with retail investors using a graphically-enhanced
online platform.

Designed to replicate the look and feel of location-based investor
conferences, Retail Investor Conferences unites PR Newswire's leading-edge
online conferencing and investor communications capabilities with
BetterInvesting's extensive retail investor audience network.


Contact: BioSpecifics Technologies Corp., Thomas L. Wegman, President,
+1-516-593-7000,;, Bradley H. Smith,,